Propanc Biopharma, Inc. Files 10-Q for Period Ending December 31, 2023

TL;DR

<b>Propanc Biopharma, Inc. filed its Q2 2024 10-Q report on February 20, 2024, detailing its financial status for the period ending December 31, 2023.</b>

AI Summary

Propanc Biopharma, Inc. (PPCB) filed a Quarterly Report (10-Q) with the SEC on February 20, 2024. Propanc Biopharma, Inc. filed a 10-Q report for the period ending December 31, 2023. The filing covers the second quarter of fiscal year 2024. The company's fiscal year ends on June 30. The filing was made on February 20, 2024. Propanc Biopharma, Inc. is in the Pharmaceutical Preparations industry (SIC 2834).

Why It Matters

For investors and stakeholders tracking Propanc Biopharma, Inc., this filing contains several important signals. This 10-Q filing provides investors with an update on Propanc Biopharma's financial performance and position as of the end of the second quarter of fiscal year 2024. Understanding the details within this report is crucial for assessing the company's operational status, financial health, and potential future trajectory in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — Propanc Biopharma, Inc. shows moderate risk based on this filing. The company's financial details are not fully available in this excerpt, making a precise risk assessment difficult. However, as a biopharmaceutical company, it inherently faces significant market and regulatory risks.

Analyst Insight

Review the full 10-Q filing to understand Propanc Biopharma's current financial standing, operational progress, and any disclosed risks or strategic initiatives.

Key Numbers

• 2023-12-31 — Period of Report End Date (10-Q filing)
• 2024-02-20 — Filing Date (10-Q filing)
• 06-30 — Fiscal Year End (Company information)
• 2834 — Standard Industrial Classification (Company information)

Key Players & Entities

• Propanc Biopharma, Inc. (company) — Filer name
• PPCB (company) — Ticker symbol
• 2023-12-31 (date) — Period of report
• 2024-02-20 (date) — Filing date
• 2834 (industry) — Standard Industrial Classification
• 06-30 (date) — Fiscal year end

FAQ

Industry Context

Propanc Biopharma operates within the pharmaceutical preparations sector, focusing on the development and commercialization of therapies.

Regulatory Implications

As a publicly traded company, Propanc Biopharma is subject to SEC regulations and reporting requirements, including the filing of quarterly 10-Q reports.

What Investors Should Do

1. Analyze the complete financial statements within the 10-Q for revenue, expenses, and cash flow.
2. Review any management discussion and analysis (MD&A) for insights into business operations and outlook.
3. Identify any new risk factors or updates to existing risks disclosed in the filing.

Key Dates

• 2023-12-31: Period of Report End Date — Marks the end of the financial reporting period covered by the 10-Q.
• 2024-02-20: Filing Date — Date the 10-Q report was officially submitted to the SEC.

Year-Over-Year Comparison

This is a 10-Q filing, providing quarterly financial information. A comparison to the previous filing (likely a 10-Q for the quarter ending September 30, 2023, or an annual 10-K) would be necessary for a detailed 'vs last filing' analysis.

Key Financial Figures

• $0.001 — hares of the registrant's common stock, $0.001 par value per share, issued and outstan

Filing Documents

• form10-q.htm (10-Q) — 2266KB
• ex31-1.htm (EX-31.1) — 11KB
• ex32-1.htm (EX-32.1) — 7KB
• 0001493152-24-007191.txt (&nbsp;) — 9693KB
• ppcb-20231231.xsd (EX-101.SCH) — 65KB
• ppcb-20231231_cal.xml (EX-101.CAL) — 67KB
• ppcb-20231231_def.xml (EX-101.DEF) — 321KB
• ppcb-20231231_lab.xml (EX-101.LAB) — 522KB
• ppcb-20231231_pre.xml (EX-101.PRE) — 428KB
• form10-q_htm.xml (XML) — 1462KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements F-1 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 3 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 9 Item 4.

Controls and Procedures

Controls and Procedures 9

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 11 Item 1A.

Risk Factors

Risk Factors 11 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 11 Item 3. Defaults Upon Senior Securities 11 Item 4. Mine Safety Disclosures 12 Item 5. Other Information 12 Item 6. Exhibits 12

Signatures

Signatures 13 2 PART I — FINANCIAL INFORMATION Item 1. Financial Statements. The following unaudited interim condensed consolidated financial statements of Propanc Biopharma, Inc. are included in this Quarterly Report on Form 10-Q: INDEX TO FINANCIAL STATEMENTS Page Condensed Consolidated Balance Sheets at December 31, 2023 (unaudited) and June 30, 2023 F-2 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and six months ended December 31, 2023 and 2022 (unaudited) F-3 Condensed Consolidated Statements of Changes in Stockholders' Deficit for each of the three and six months in the periods ended December 31, 2023 and 2022 (unaudited) F-4 Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2023 and 2022 (unaudited) F-5 Notes to the Condensed Consolidated Financial Statements (unaudited) F-6 F-1 PROPANC BIOPHARMA, INC. AND SUBSIDIARY PROPANC BIOPHARMA, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2023 June 30, 2023 (Unaudited) ASSETS CURRENT ASSETS: Cash $ 71,650 $ 10,047 GST tax receivable 3,908 2,867 Prepaid expenses and other current assets 12,139 6,125 Refundable advance deposit 123,127 - TOTAL CURRENT ASSETS 210,824 19,039 Security deposit - related party 2,044 1,999 Operating lease right-of-use assets, net - related party 28,989 38,988 Property and equipment, net 50 302 TOTAL ASSETS $ 241,907 $ 60,328 LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES: Accounts payable $ 1,157,691 $ 966,718 Accrued expenses and other payables 689,594 579,707 Accrued interest 66,319 44,709 Loan payable 65,280 65,280 Loans payable - related party 16,429 - Loans payable 16,429 - Note payable, net of discount 132,000 - Convertible notes, net of discounts and including put premiums 687,650 390,539 Operating lease liability - related party, current portion 22

View Full Filing

View this 10-Q filing on SEC EDGAR